90 related articles for article (PubMed ID: 25137174)
21. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
22. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
Liapis K; Harhalakis N; Stefanou G; Apostolidis J
J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
[No Abstract] [Full Text] [Related]
23. Effect of intravitreous rituximab injections in patients with recurrent ocular lesions associated with central nervous system lymphoma.
Ohguro N; Hashida N; Tano Y
Arch Ophthalmol; 2008 Jul; 126(7):1002-3. PubMed ID: 18625954
[No Abstract] [Full Text] [Related]
24. Rituximab maintenance in follicular lymphoma: PRIMA.
Friedberg JW
Lancet; 2011 Jan; 377(9759):4-6. PubMed ID: 21176951
[No Abstract] [Full Text] [Related]
25. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
[TBL] [Abstract][Full Text] [Related]
26. Remission of transient acantholytic dermatosis after the treatment with rituximab for follicular lymphoma.
Ishibashi M; Nagasaka T; Chen KR
Clin Exp Dermatol; 2008 Mar; 33(2):206-7. PubMed ID: 18076680
[No Abstract] [Full Text] [Related]
27. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
28. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
29. Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy.
Mercadal S; Pomares H; Sancho JM; Climent F; García O; Encuentra M; Domingo-Doménech E; Sorigué M; Moreno M; Oliveira AC; Ribera JM; Fernández de Sevilla A; González-Barca E
Br J Haematol; 2016 Feb; 172(3):470-3. PubMed ID: 26010479
[No Abstract] [Full Text] [Related]
30. Ocular adnexal follicular lymphoma: a multicenter international study.
Rasmussen PK; Coupland SE; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; McKelvie P; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Heegaard S
JAMA Ophthalmol; 2014 Jul; 132(7):851-8. PubMed ID: 24763920
[TBL] [Abstract][Full Text] [Related]
31. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
Askeland G
Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
[No Abstract] [Full Text] [Related]
32. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.
Salar A; Avivi I; Bittner B; Bouabdallah R; Brewster M; Catalani O; Follows G; Haynes A; Hourcade-Potelleret F; Janikova A; Larouche JF; McIntyre C; Pedersen M; Pereira J; Sayyed P; Shpilberg O; Tumyan G
J Clin Oncol; 2014 Jun; 32(17):1782-91. PubMed ID: 24821885
[TBL] [Abstract][Full Text] [Related]
33. Rituximab by subcutaneous route.
Solal-Celigny P
Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
[TBL] [Abstract][Full Text] [Related]
34. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
35. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
36. Maintenance rituximab should be considered for patients with follicular lymphoma.
Barr PM
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541-3. PubMed ID: 25356579
[No Abstract] [Full Text] [Related]
37. Rituximab maintenance therapy for follicular lymphoma.
Zhou H; Zhang B; Zhang J; Ni W; Hu Z
Lancet; 2011 Apr; 377(9772):1150-1; author reply 1151-2. PubMed ID: 21459204
[No Abstract] [Full Text] [Related]
38. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.
Davies A; Merli F; Mihaljevic B; Siritanaratkul N; Solal-Céligny P; Barrett M; Berge C; Bittner B; Boehnke A; McIntyre C; Macdonald D
Lancet Oncol; 2014 Mar; 15(3):343-52. PubMed ID: 24521993
[TBL] [Abstract][Full Text] [Related]
39. Edema of the eyelids and sclera after rituximab infusion for orbital MALT lymphoma.
Oribe N; Tanimoto TE; Shimoda K; Hikiji W; Mitsugi K; Takase K; Henzan H; Numata A; Miyamoto T; Fukuda T; Nagafuji K; Harada M
Haematologica; 2004 Jun; 89(6 Suppl):EIM14. PubMed ID: 15194556
[No Abstract] [Full Text] [Related]
40. Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Tuccori M; Focosi D; Blandizzi C; Del Tacca M; Petrini M
J Natl Cancer Inst; 2009 Sep; 101(18):1288-9; author reply 1289-90. PubMed ID: 19687414
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]